BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Daiichi Pharmaceutical Co., Ltd. Names Dr. Jay Feingold Vice President, Medical Affairs Bolsters Company's Expertise in Areas of Oncology and Hematology


2/11/2010 10:50:04 AM

PARSIPPANY, N.J., Feb. 11 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. (DSI) announced today that Jay M. Feingold, M.D., Ph.D., has been appointed Vice President of Medical Affairs. Dr. Feingold will manage strategic direction of the company's Medical Affairs department and oversee more than 90 scientists, researchers and field-based medical teams responsible for collaborating with the company's clinical research arm, commercial organization and partners. Medical Affairs is responsible for providing physicians, key opinion leaders, regulatory agencies and professional organizations with medical and scientific information in the areas of clinical studies, outcomes research and disease management programs, among others. Dr. Feingold's vast experience in oncology and hematology will continue to drive the company's current cardiovascular portfolio and shape its pipeline.

Dr. Feingold also becomes a member of DSI's Executive Committee, which is responsible for guiding the organization's short- and long-term strategic and financial objectives.

Prior to joining DSI, Dr. Feingold worked with Wyeth Pharmaceuticals, where he most recently led Oncology Global Clinical Development. Prior to that, he was multi-therapeutic area head in Global Medical Affairs with responsibility for the hematology, oncology and central nervous system (CNS) franchises.

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator. The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. A central focus of Daiichi Sankyo's research

Daiichi Sankyo, Inc.




Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES